Acquired chemotherapy resistance in ovarian cancer

被引：166

作者：

Christie, E. L. ^{[1
,2
]}

Bowtell, D. D. L. ^{[1
,2
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

基金：

英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;

关键词：

ovarian cancer; platinum-resistant; relapse; heterogeneity; ctDNA; MUTATIONS; INHIBITION; DNA;

D O I：

10.1093/annonc/mdx446

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Most women diagnosed with high-grade serous ovarian cancer (HGSC) develop recurrent disease and chemotherapy resistance, despite initially responding to treatment. The genomic characteristics of HGSC samples collected at initial surgery have been extensively studied. However, due to challenges of sample collection following treatment, much less is known about the molecular features of recurrent disease. Our recent studies have identified mechanisms of acquired resistance and biomarkers in recurrent HGSCs that could lead to improved treatment approaches.

引用

页码：13 / 15

页数：3

共 14 条

[1]

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary [J].

Ahmed, Ashour Ahmed ;

Etemadmoghadam, Dariush ;

Temple, Jillian ;

Lynch, Andy G. ;

Riad, Mohamed ;

Sharma, Raghwa ;

Stewart, Colin ;

Fereday, Sian ;

Caldas, Carlos ;

DeFazio, Anna ;

Bowtell, David ;

Brenton, James D. .

JOURNAL OF PATHOLOGY, 2010, 221 (01) :49-56

[2]

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].

Alsop, Kathryn ;

Fereday, Sian ;

Meldrum, Cliff ;

deFazio, Anna ;

Emmanuel, Catherine ;

George, Joshy ;

Dobrovic, Alexander ;

Birrer, Michael J. ;

Webb, Penelope M. ;

Stewart, Colin ;

Friedlander, Michael ;

Fox, Stephen ;

Bowtell, David ;

Mitchell, Gillian .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663

[3]

Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[4]

Standard treatment in advanced ovarian cancer in 2005: the state of the art [J].

Bookman, MA .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 :212-220

[5]

Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer [J].

Christie, Elizabeth L. ;

Fereday, Sian ;

Doig, Ken ;

Pattnaik, Swetansu ;

Dawson, Sarah-Jane ;

Bowtell, David D. L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (12) :1274-1280

[6]

Evolution of platinum resistance in high-grade serous ovarian cancer [J].

Cooke, Susanna L. ;

Brenton, James D. .

LANCET ONCOLOGY, 2011, 12 (12) :1169-1174

[7]

LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin [J].

Cowin, Prue A. ;

George, Joshy ;

Fereday, Sian ;

Loehrer, Elizabeth ;

Van Loo, Peter ;

Cullinane, Carleen ;

Etemadmoghadam, Dariush ;

Ftouni, Sarah ;

Galletta, Laura ;

Anglesio, Michael S. ;

Hendley, Joy ;

Bowes, Leanne ;

Sheppard, Karen E. ;

Christie, Elizabeth L. ;

Pearson, Richard B. ;

Harnett, Paul R. ;

Heinzelmann-Schwarz, Viola ;

Friedlander, Michael ;

McNally, Orla ;

Quinn, Michael ;

Campbell, Peter ;

deFazio, Anna ;

Bowtell, David D. L. .

CANCER RESEARCH, 2012, 72 (16) :4060-4073

[8]

Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer [J].

Etemadmoghadam, Dariush ;

George, Joshy ;

Cowin, Prue A. ;

Cullinane, Carleen ;

Kansara, Maya ;

Gorringe, Kylie L. ;

Smyth, Gordon K. ;

Bowtell, David D. L. .

PLOS ONE, 2010, 5 (11)

[9]

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition [J].

Lheureux, Stephanie ;

Bruce, Jeff P. ;

Burnier, Julia V. ;

Karakasis, Katherine ;

Shaw, Patricia A. ;

Clarke, Blaise A. ;

Yang, S. Y. Cindy ;

Quevedo, Rene ;

Li, Tiantian ;

Dowar, Mark ;

Bowering, Valerie ;

Pugh, Trevor J. ;

Oza, Amit M. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (11) :1240-1249

[10]

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas [J].

Norquist, Barbara ;

Wurz, Kaitlyn A. ;

Pennil, Christopher C. ;

Garcia, Rochelle ;

Gross, Jenny ;

Sakai, Wataru ;

Karlan, Beth Y. ;

Taniguchi, Toshiyasu ;

Swisher, Elizabeth M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :3008-3015

← 1 2 →